GNI Group Ltd.(2160) Summary
2160
TSE Growth
GNI Group Ltd.
Result
ー
2,872
JPY
+67
(+2.39%)
Sep 4, 3:30 pm JST
18.38
USD
Sep 4, 2:30 am EDT
PER
ー
PBR
4.67
Yield
ー%
Margin Trading Ratio
10.90
PTS
outside of trading hours
2,870
Sep 4, 10:47 pm JST
Stock Price
Sep 4, 2026
Opening
Sep 4, 9:00 am
2,841
JPY
18.25
USD
Previous Close
Sep 3
2,805
JPY
17.83
USD
High
Sep 4, 2:24 pm
2,875
JPY
18.42
USD
Low
Sep 4, 9:14 am
2,806
JPY
18.03
USD
Volume
741,800
Trading Value
2.12B
JPY
0.01B
USD
VWAP
2850.69
JPY
18.25
USD
Minimum Trading Value
287,200
JPY
1,838
USD
Market Capitalization
0.19T
JPY
1.21B
USD
Number of Trades
2,532
Opening
Sep 4, 6:10 pm
2,871
JPY
Previous Close
Sep 4
ー
JPY
High
Sep 4, 6:36 pm
2,872
JPY
Low
Sep 4, 10:47 pm
2,870
JPY
Volume
800
Trading Value
2.29M
JPY
VWAP
2,871.50
JPY
Minimum Trading Value
ー
Market Capitalization
ー
Number of Trades
ー
PTS Stock Price
Liquidity & Number of Trades
As of Sep 4, 2026
Liquidity
Liquidity Grade
| Liquidity | Number Of Trades | Distribution |
|---|---|---|
| High | Over 1,000 | 13.9% |
| Slightly-High | 400 to 1,000 | 18.5% |
| Mid | 50 to 400 | 39.0% |
| Slightly-Low | 10 to 50 | 17.6% |
| Low | Less than 10 | 11.0% |
High
1-Year Average
3,098
1-Year High
Jan 6, 2026
14,020
Margin Trading
| Date | Short Interest | Long Margin Positions | Ratio |
|---|---|---|---|
| Aug 28, 2026 | 717,300 | 7,818,300 | 10.90 |
| Aug 21, 2026 | 700,300 | 7,909,400 | 11.29 |
| Aug 14, 2026 | 687,600 | 7,292,400 | 10.61 |
| Aug 7, 2026 | 675,300 | 7,242,400 | 10.72 |
| Jul 31, 2026 | 654,300 | 7,448,400 | 11.38 |
Similar Stocks
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
Website
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.